EPS

AGCO's stock plunged after a surprise guidance cut, triggering a legal probe. We dissect if this was just a market downturn or a failure in transparency.

The $204.6M deal creates an $8.3B regional powerhouse, raising questions about local impact, shareholder value, and the future of community banking.

ITW’s 63rd consecutive dividend hike and a $6B buyback signal profound confidence. What do these moves reveal about the industrial giant's strategy?

Despite a slight revenue dip, Ultralife Corp. tripled its earnings per share. A look at how operational discipline and a record order book are charting its course.

Amid falling earnings and regulatory battles, Algonquin Power & Utilities is redomiciling to the U.S. A look at the strategy behind the corporate shift.

Despite a revenue dip, Embecta's stock soared after crushing Q3 profit estimates, signaling its strategic pivot beyond insulin is starting to pay off.

Interface posted stellar Q2 results, but a one-time $15.6M tariff refund inflated the numbers. The real story is the operational resilience of its strategy.

DouYu names a new CEO after the former chief's 'personal' exit, but a history of arrests and regulatory probes tells a deeper story of strategic survival.

AIG's strong Q2 results beat profit estimates, powered by underwriting discipline as it completes its strategic pivot away from Corebridge Financial.

ESCO Technologies reports a stellar Q3 with 38% adjusted EPS growth and a record $1.5B backlog, proving its acquisition strategy is a powerful engine for growth.

Karat Packaging's profits surged 168% thanks to a massive one-time tariff refund. A deep dive reveals the real story lies in its strategic growth.

Arlo Technologies smashed expectations with record revenue, fueled by a masterful pivot to recurring services that now form the core of its business.

The software supply chain firm's Q2 results beat estimates, with cloud revenue soaring 53% as its security platform becomes essential for the AI era.

Resmed posts record revenue and boosts shareholder returns, but its strategic pivot and operational hurdles reveal a more complex story of medtech leadership.

Beyond the mixed GAAP results, ICU Medical’s strong non-GAAP growth and raised guidance reveal a company thriving after a strategic pivot.

International Bancshares reports steady half-year growth but a Q2 dip, revealing a strategy of proactive risk management and AI-driven efficiency.

Amid a booming Alberta energy sector, AKITA Drilling launches a major share buyback, signaling deep confidence in its value while balancing debt reduction.

Amphastar beats Q2 estimates with new drug sales, but a deeper look reveals pricing pressure, rising costs, and a high-stakes bet on its pipeline.

Amphenol's stock split and dividend aren't just financial housekeeping. They're a bold signal of confidence in the booming tech hardware market. Here's why.

With a 32% jump in royalty revenue and a game-changing acquisition, Ligand Pharmaceuticals solidifies its market dominance. But is the growth sustainable?